Azolla has co-evolved with the cyanobacterial symbiont Anabaena azollae for approximately 80 million years, resulting in extensive genetic exchange between the two partners. Azolla and its symbiont therefore contain unique sets of genes and biochemicals that we are developing as pharmaceuticals and nutraceuticals. These include potential cures for a variety of neurogenerative diseases, including amyotrophic lateral sclerosis/parkinsonism–dementia complex (ALS/PDC), which have been linked to the cyanotoxin β-Methylamino-L-alanine (BMAA).

Our technology is presently confidential and subject to copyright and patents